Dyne Therapeutics (NASDAQ:DYN) Receives Buy Rating from Guggenheim

Guggenheim reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report report published on Friday morning,Benzinga reports.

A number of other equities research analysts have also recently weighed in on DYN. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Chardan Capital reissued a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $13.72 on Friday. The business’s fifty day moving average price is $24.03 and its 200 day moving average price is $32.63. The firm has a market capitalization of $1.40 billion, a PE ratio of -3.85 and a beta of 1.16. Dyne Therapeutics has a 1-year low of $13.44 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities research analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jason P. Rhodes sold 782 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares of the company’s stock, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,071 shares of company stock worth $606,476. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently bought and sold shares of the stock. abrdn plc acquired a new stake in shares of Dyne Therapeutics during the 4th quarter worth $608,000. China Universal Asset Management Co. Ltd. grew its position in Dyne Therapeutics by 11.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock valued at $508,000 after acquiring an additional 2,265 shares during the period. KBC Group NV increased its stake in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Dyne Therapeutics by 4.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company’s stock worth $3,655,000 after purchasing an additional 4,236 shares during the period. Finally, Virtue Capital Management LLC lifted its stake in shares of Dyne Therapeutics by 4.4% in the 3rd quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock valued at $834,000 after purchasing an additional 981 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.